2333 GMT - Licensing income from the Daybue treatment for Rett Syndrome alone supports Neuren Pharmaceuticals's share price, meaning investors effectively get exposure to its next drug candidate "for free," Bell Potter says. Neuren is upbeat about the potential of NNZ-2591 as a treatment of several neurodevelopmental disorders. It has cited positive results from Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Still, Bell Potter says it will be two years until Neuren's next major clinical catalyst: the first Phase 3 trial results for NNZ-2591. "Neuren has unrivalled balance sheet strength to prosecute future NNZ-2591 development yet effectively zero value is currently attributed to this asset, likely due to the Phase 3 readout timing," analyst Thomas Wakim says. Bell Potter retains a "buy" call on Neuren. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
March 11, 2025 19:33 ET (23:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.